Eric P. Winer
Impact in
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer survivorship and care
Papers in
- Cancer Research 221
- Breast Cancer Treatment Studies 215
- Oncology 195
- HER2/EGFR in Cancer Research 83
- Cancer survivorship and care 31
- Cancer Immunotherapy and Biomarkers 21
- Cancer Treatment and Pharmacology 20
- Co-authors
- Adrienne Gropper Waks (13 shared papers)Harold Burstein (87 shared papers)NU Lin (106 shared papers)Ann H. Partridge (98 shared papers)Clifford A. Hudis (80 shared papers)Hope S. Rugo (38 shared papers)Lisa A. Carey (44 shared papers)Donald A. Berry (36 shared papers)
- Journals
- Journal of Clinical Oncology (140 papers)Annals of Oncology (70 papers)Breast Cancer Research and Treatment (60 papers)Clinical Cancer Research (42 papers)JNCI Journal of the National Cancer Institute (29 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Eric P. Winer
710 papers receiving 95.7k citations
Eric P. Winer's Hit Papers
Peers
Comparison fields: 5 of 146
- Cancer Research 26.8k
- Oncology 19.4k
- Pulmonary and Respiratory Medicine 11.2k
- Family Practice 639
- Geriatrics and Gerontology 386
Countries citing papers authored by Eric P. Winer
This map shows the geographic impact of Eric P. Winer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric P. Winer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric P. Winer more than expected).
Fields of papers citing papers by Eric P. Winer
This network shows the impact of papers produced by Eric P. Winer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric P. Winer. The network helps show where Eric P. Winer may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric P. Winer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 730 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Breast Cancer Treatment Hit paper breakdown → | 2019 | 3629 |
| 2 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 3493 |
| 3 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Hit paper breakdown → | 2013 | 2987 |
| 4 | 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) Hit paper breakdown → | 2016 | 1808 |
| 5 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Hit paper breakdown → | 2016 | 1564 |
| 6 | American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Hit paper breakdown → | 2005 | 1499 |
| 7 | Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Hit paper breakdown → | 2015 | 1470 |
| 8 | Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 Hit paper breakdown → | 2003 | 1271 |
| 9 | CDK4/6 inhibition triggers anti-tumour immunity Hit paper breakdown → | 2017 | 1187 |
| 10 | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Hit paper breakdown → | 2009 | 1147 |
| 11 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Hit paper breakdown → | 2020 | 1029 |
| 12 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2019 | 992 |
| 13 | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 975 |
| 14 | Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343 Hit paper breakdown → | 2013 | 970 |
| 15 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Hit paper breakdown → | 2017 | 918 |
| 16 | 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) Hit paper breakdown → | 2018 | 884 |
| 17 | Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials Hit paper breakdown → | 2017 | 859 |
| 18 | Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets Hit paper breakdown → | 2015 | 858 |
| 19 | 2004 | 841 | |
| 20 | Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Hit paper breakdown → | 2016 | 841 |
About Eric P. Winer
Eric P. Winer is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Public Health, Environmental and Occupational Health and Genetics, having authored 730 papers that have together received 98.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (215 papers), HER2/EGFR in Cancer Research (83 papers), Advanced Breast Cancer Therapies (37 papers), Brain Metastases and Treatment (31 papers), Cancer survivorship and care (31 papers), Cancer Immunotherapy and Biomarkers (21 papers), Cancer Treatment and Pharmacology (20 papers) and BRCA gene mutations in cancer (17 papers). The work is most often cited by research in Cancer Research (26.8k citations), Oncology (19.4k citations), Pulmonary and Respiratory Medicine (11.2k citations), Family Practice (639 citations) and Geriatrics and Gerontology (386 citations). Eric P. Winer has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Adrienne Gropper Waks, Harold Burstein, NU Lin, Ann H. Partridge, Clifford A. Hudis, Hope S. Rugo, Lisa A. Carey, Donald A. Berry, Ian E. Krop and Constance Cirrincione. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Breast Cancer Research and Treatment, Clinical Cancer Research and JNCI Journal of the National Cancer Institute.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.